# Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/health-loss-due-to-market-access-delays-and-reimbursement-restrictions-in-first/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kirsten van Nimwegen,K Nientker,Sophie Boukouvalas |
| Citations | 0 |
| DOI | 10.1016/j.jval.2017.08.376 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2765136712 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Kirsten van Nimwegen](https://scholariq.org/researchers/kirsten-van-nimwegen/)

## Paper journal

- [Value in Health](https://scholariq.org/journals/value-in-health/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.